New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
February 01, 2024 01:03 ET
|
F. Hoffmann-La Roche Ltd
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months...
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
December 04, 2023 07:30 ET
|
Atsena Therapeutics
ATSN-101 continues to demonstrate clinically meaningful improvements in vision at the highest dose and is well-tolerated 12 months post-treatmentData accepted for presentation at 47th Annual Macula...
Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
March 08, 2023 07:00 ET
|
Viridian Therapeutics, Inc
- Positive data reported from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid eye disease (TED) - - First patient enrolled in ‘THRIVE’ Phase 3 trial in patients with...
Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society
March 07, 2023 08:00 ET
|
Viridian Therapeutics, Inc
- Data from ongoing Phase 1/2 trial of VRDN-001 to be presented during oral platform session - - Additional poster presentations to cover trial design, early-stage clinical and mechanistic data...
Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society Meeting
February 08, 2023 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
January 26, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Asensus Surgical to Participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
November 28, 2022 06:55 ET
|
Asensus Surgical, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Shameze Rampertab, Executive Vice President and Chief Financial...
Atsena Therapeutics Announces Presentations at ARVO 2022 Annual Meeting and ASGCT 25th Annual Meeting
May 02, 2022 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors
January 04, 2022 09:00 ET
|
Tarsus Pharmaceuticals, Inc
Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation IRVINE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tarsus...
MidWest Eye Center, Cincinnati’s Leading Custom LASIK Eyecare Provider, Welcomes 5 Highly-Skilled Additions to the Team.
October 20, 2021 08:42 ET
|
MidWest Eye Center
Cincinnati, Ohio, Oct. 20, 2021 (GLOBE NEWSWIRE) -- The MidWest Eye Center is Cincinnati and Northern Kentucky’s leader for complete eyecare, from diagnosis to surgical and non-surgical treatments...